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Early Abciximab Improves TIMI Score for ST-Segment Elevation MIs
Glycoprotein IIb/IIIa inhibitors improve myocardial reperfusion in patients withacute myocardial infarction (MI) but whether they should be started in the
emergency room (ER) or after initial angiography remains unclear. Maioli and col-
leagues randomized approximately 200 patients presenting to their institution with
acuteMI to either abciximab in the ER or just before percutaneous coronary interven-
tion (PCI). The average door-to-balloon time was similar in both groups (90 min),
but patients who received abciximab in the ER received it an average of 41min earlier.
This was associated with a nearly 3-fold greater likelihood of Thrombolysis In Myo-
cardial Infarction (TIMI) flow grade 3, improved myocardial blush grade, and better
left ventricular function. This study suggests that in patients with acute MI, early
abciximab administration improves pre-PCI angiographic findings, post-PCI tissue
perfusion, and left ventricular function, probably via early recanalization of the infarct-
related artery. See page 1517.
Page 1531
Myocardial Infarction
Novel Biomarker Enhances the Prognostic Utility of BNP
Adrenomedullin (ADM) is a 52 amino acid peptide originally isolated fromhumanpheochromocytoma cells but subsequently found to be highly expressed in
endothelial cells. Adrenomedullin signals through cyclic adenosine monophosphate
and has biologic activity similar to B-type natriuretic peptide (BNP) causing vasodila-
tion via production of nitric oxide, increasing cardiac output and inducing natriuresis.
Khan and colleagues measured plasma levels of ADM in nearly 1,000 post-acute
myocardial infarction patients, 3 to 5 days after chest pain onset. Adrenomedullin was
higher in patients with poor outcomes; it was particularly useful in further risk
stratifying subjects with elevated BNP. This study suggests that ADM is released into
the circulation following acutemyocardial infarction andmay provide useful prognos-
tic information, especially in those with elevated BNP levels. See page 1525. See
figure.
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Atherosclerosis
Metabolic Syndrome Linked to Carotid Inflammation
Recent studies have demonstrated that [
18F]-fluorodeoxyglucose (FDG) positron
emission tomography (PET) can identify and quantify the degree of inflamma-
tion within carotid artery plaques. Tahara and colleagues studied over 200 patients
referred for FDG-PET and measured several cardiac risk factors. The results revealed
that waist circumference, use of hypertensivemedication, low high-density lipoprotein
cholesterol, insulin resistance, and high-sensitivity C-reactive protein were significant
independent predictors of carotid inflammation. Furthermore, the number of compo-
nents of the metabolic syndrome that a subject had was quantitatively related to the
degree of inflammation. This study confirms that increased inflammation in carotid
plaques is found in subjects with the components of the metabolic syndrome. See
page 1533. See figure.
(continued) A-32Heart Disease in Women
Comparing Female and Male Atherosclerotic Plaques With IVUS
Most large-scale clinical trials have fewer female participants. Nicholls and col-leagues compared female and male participants in the 3 large-scale trials that
included serial intravascular ultrasound (IVUS) exams. Female participants in these
studies had higher levels of body mass index, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides, C-reactive protein, systolic blood
pressure, and diastolic blood pressure. Despite this, females had less plaque in terms of
percent atheroma volume (PAV) and total atheroma volume (TAV). With medical
therapy, males and females had similar changes in both PAV and TAV. This study
suggests that despite the presence ofmore risk factors, the extent of atheroma in females
with angiographic coronary artery disease is less than in males, but there were no
differences in the rates of plaque progression or regression, or in response to medical
therapy. See page 1546.
Pulmonary Vascular Disease
Infusion of EPCs Helpful for Pulmonary Hypertension
The etiology of idiopathic pulmonary arterial hypertension (IPAH) is poorlyunderstood. Wang and colleagues hypothesized that infusion of autologous-
derived endothelial progenitor cells (EPCs) might improve outcomes by restoring a
healthy endothelium. Thirty-one subjects with IPAHwere randomized to either EPC
infusion or conventional therapy. After 12 weeks, the mean distance covered in the
6-minwalk test increased by 48.2m (nearly 20%)with EPC infusion versus only a 2%
change in the conventional therapy group.Therewere also significant improvements in
pulmonary vascular resistance and cardiac output; there were no obvious toxicities or
adverse events related to the infusion. Autologous transplantion of EPCsmay be a safe
and effective therapy for IPAH, although larger and longer-term studies are clearly
needed. See page 1566.
